HER2+ breast cancer: How to evaluate?

Advances in Therapy

Volumn 26, Issue SUPPL.1, 2009, Pages

  Schmitt, Fernando ^a  

^a University of Porto   (Portugal)

Author keywords

Breast cancer; FISH; HER2 positive; Immunohistochemistry; PTEN; Trastuzumab

Indexed keywords

CETUXIMAB; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MUCIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN RECEPTOR; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RESISTANCE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MEMBRANE PROTEINS; PTEN PHOSPHOHYDROLASE; RECEPTOR, ERBB-2; SENSITIVITY AND SPECIFICITY;

EID: 74049150299     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-009-0046-1     Document Type: Review

References (31)

1. C.I. Li D.J. Uribe J.R. Daling 2005 Clinical characteristics of different histologic types of breast cancer Br J Cancer 93 1046 1052 16175185 10.1038/sj.bjc.6602787 1:STN:280:DC%2BD2MrntFWrsQ%3D%3D (Pubitemid 41548400)
2. C.I. Li R.E. Moe J.R. Daling, et al. 2003 Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years Arch Intern Med 163 2149 2153 14557212 10.1001/archinte.163.18.2149 (Pubitemid 37248779)
3. J. Brenton L. Carey A.A. Ahmed, et al. 2005 Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 7350 7360 16145060 10.1200/JCO.2005.03.3845 1:CAS:528:DC%2BD2MXhtF2nsLrJ (Pubitemid 46202348)
4. E.A. Rakha D.S. Tan W.D. Foulkes, et al. 2007 Are triple-negative tumours and basal-like breast cancer synonymous? Breast Cancer Res 9 404 18279542 10.1186/bcr1827
5. C.R. King M.H. Kraus S.A. Aaronson, et al. 1985 Amplification of a novel v-erbB-related gene in a human mammary carcinoma Science 229 974 976 2992089 10.1126/science.2992089 1:CAS:528:DyaL2MXlsFGit7k%3D
6. D. Karunagaran E. Tzahar R.R. Beerli, et al. 1996 ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer EMBO J 15 254 264 8617201 1:CAS:528:DyaK28XovFSksQ%3D%3D
7. N.E. Hynes H.A. Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354 15864276 10.1038/nrc1609 1:CAS:528:DC%2BD2MXjslertb0%3D (Pubitemid 40637826)
8. A. Citri Y. Yarden 2006 EGF-ERBB signaling: towards the systems level Nat Rev Mol Cell Biol 7 505 516 16829981 10.1038/nrm1962 1:CAS:528:DC%2BD28Xms1OhsLc%3D (Pubitemid 44036456)
9. M. Moasser 2007 The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 6469 6487 17471238 10.1038/sj.onc.1210477 1:CAS:528:DC%2BD2sXhtFagsbnN (Pubitemid 47530601)
10. Y. Yarden M.X. Sliwkowski 2001 Untangling the ErbB signalling network Nat Rev Mol Cell Biol 2 127 137 11252954 10.1038/35052073 1:CAS:528:DC%2BD3MXivVWnt7k%3D (Pubitemid 33674041)
11. D.J. Slamon G.M. Clark S.G. Wong W.J. Levin A. Ullrich W.L. McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 3798106 10.1126/science.3798106 1:CAS:528:DyaL2sXhtVSht7s%3D
12. J.S. Ross J.A. Fletcher G.P. Linette, et al. 2003 The Her-2/neu gene and protein in breast cancer biomarker and target of therapy Oncologist 8 307 325 12897328 10.1634/theoncologist.8-4-307 1:CAS:528:DC%2BD3sXmvFSqt74%3D (Pubitemid 36929717)
13. A.C. Wolff M.E. Hammond J.N. Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 8 43
14. E.H. Romond E.A. Perez J. Bryant, et al. 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 16236738 10.1056/NEJMoa052122 1:CAS:528:DC%2BD2MXhtFansr3F (Pubitemid 41464706)
15. M.J. Piccart-Gebhart M. Procter B. Leyland-Jones, et al. 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 16236737 10.1056/NEJMoa052306 1:CAS:528:DC%2BD2MXhtFansr3L (Pubitemid 41464705)
16. Slamon, D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastsuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2neu positive early breast cancer patients. Presented at: 29th Annual Meeting of the San Antonio Breast Cancer Symposium; Dec 14-18, 2006; San Antonio, TX, USA.
17. H. Joensuu P.L. Kellokumpu-Lehtinen P. Bono, et al. 2006 Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer N Engl J Med 354 809 820 16495393 10.1056/NEJMoa053028 1:CAS:528:DC%2BD28Xhsl2gsrY%3D (Pubitemid 43290919)
18. The Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab following adjuvant chemotherapy in HER2-positive early stage breast cancer (HERA trial): disease-free and overall survival after 2 year follow-up. Presented as a late breaking abstract at: 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006; Atlanta, GA, USA.
19. P.P. Pandolfi 2004 Breast cancer-loss of PTEN predicts resistance to treatment N Engl J Med 351 2337 2338 15564551 10.1056/NEJMcibr043143 1:CAS:528:DC%2BD2cXhtValtrrN (Pubitemid 39552753)
20. L.N. Harris F. You S.J. Schnitt, et al. 2007 Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer Clin Cancer Res 13 1198 1207 17317830 10.1158/1078-0432.CCR-06-1304 1:CAS:528:DC%2BD2sXhvF2hsbo%3D (Pubitemid 46424061)
21. M.M. Moasser 2007 The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis Oncogene 26 6469 6487 17471238 10.1038/sj.onc.1210477 1:CAS:528:DC%2BD2sXhtFagsbnN (Pubitemid 47530601)
22. M. Scaltriti F. Rojo A. Ocaña, et al. 2007 Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer J Natl Cancer Inst. 2 99 628 638 10.1093/jnci/djk134 1:CAS:528:DC%2BD2sXlvVSktr4%3D (Pubitemid 47073544)
23. A.C. Wolff M.E. Hammond J.N. Schwartz, et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118 145 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D (Pubitemid 350003059)
24. E.A. Perez V.J. Suman N.E. Davidson, et al. 2006 HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial J Clin Oncol 24 3032 3038 16809727 10.1200/JCO.2005.03.4744 (Pubitemid 46638937)
25. P.C. Roche V.J. Suman R.B. Jenkins 2002 Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 J Natl Cancer Inst 94 855 857 12048274
26. S. Paik J. Bryant E. Tan-Chiu 2002 Real-world performance of HER2 testing - national surgical adjuvant breast and bowel project experience J Natl Cancer Inst 94 852 854 12048273
27. Milanezi F. [Avaliação do HER2/neu em carcinomas invasivos da mama: correlação entre estudo imunohistoquímico e hibridização in situ por fluorescência.] Masters Thesis, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. 2004. In Portugu
28. M. Bilous M. Dowsett W. Hanna, et al. 2003 Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173 182 12591971 10.1097/01.MP.0000052102.90815.82 (Pubitemid 36245750)
29. R.A. Walker J.M. Bartlett M. Dowsett, et al. 2008 HER2 testing in the UK: further update to recommendations J Clin Pathol 61 818 824 18381380 10.1136/jcp.2007.054866 1:STN:280:DC%2BD1cvhsFegsQ%3D%3D (Pubitemid 351969725)
30. S.A. Ricardo F. Milanezi S.T. Carvalho, et al. 2007 HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas J Clin Pathol 60 1001 1005 17158643 10.1136/jcp.2006.040287 (Pubitemid 47441932)
31. F. Milanezi S. Carvalho F. Schmitt 2008 EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy Expert Rev Mol Diagn 8 417 434 18598224 10.1586/14737159.8.4.417 1:CAS:528:DC%2BD1cXotFOqt78%3D (Pubitemid 351962088)